SWK Holdings Corporation 9.00% Senior Notes due 2027

What they do

SWK Holdings operates a Finance Receivables segment that provides customized financing solutions to life science companies, primarily through royalty purchases, synthetic revenue interests, and secured term loans. The company targets transactions under $50 million, an underserved niche, and generates income from interest, fees, and royalties tied to the sales of life science products. As of March 7, 2026, it has funded approximately $876.1 million across 58 transactions since inception.

Revenue drivers

• Finance Receivables – Royalty purchases and synthetic royalties — Generates income by purchasing or financing royalties from commercial-stage life science products; includes products like Iluvien, Besivance, and Cambia, though many were monetized in 2025.
• Finance Receivables – Secured term loans — Provides first-lien debt to life science companies; notable borrowers include 4Web, Inc. ($19.5M principal, 12.8% rate) and AOTI, Inc. ($19.5M principal, 13.0% rate).
• Pharmaceutical Development (sold in Q3 2025) — Former segment operated MOD3 Pharma (contract manufacturing and licensing); substantially all assets were sold, with the segment removed as a reportable segment after Q3 2025.

Recent performance

In Q3 2025, SWK reported GAAP net income of $8.8 million ($0.72 per diluted share), up from $3.5 million in Q3 2024, driven by earlier loan payoffs, warrant gains, and the MOD3 sale. Finance receivables segment adjusted non-GAAP net income was $8.1 million, and the effective yield reached 16.9%, a 230 basis point increase year-over-year. For full-year 2025, revenue was $2.2M and net income was negative $2.5M, reflecting the sale of the Pharma segment and one-time items. Net finance receivables were $245.4 million at September 30, 2025, down 4.1% from a year earlier, after monetizing $51.3 million of royalty assets in the first half of 2025. The company paid a $4.00 per share special dividend in Q2 2025.

Strategy

SWK focuses on maximizing total return from its finance receivables portfolio through a mix of debt, royalty, and equity-related investments, with a prudent risk approach. It targets transactions below $50 million, where larger competitors are less focused. The company has been actively managing its portfolio, including selling substantially all of its Pharmaceutical Development assets and monetizing a majority of its royalty assets in 2025. It also repurchased shares: 87,927 shares in Q3 2025 and 199,218 year-to-date through October 28, 2025. Post-merger, the company will operate solely as a finance receivables business.

Risks

• Concentration risk — The finance receivables portfolio has a limited number of assets, so a default or underperformance of a single royalty or loan could significantly impact overall returns and stock value.
• Credit loss risk — Most assets are debt or royalties tied to small and middle-market life science companies that are speculative and carry a high degree of principal loss risk if underlying products fail to generate expected revenues.
• Third-party dependence — The company relies on partner companies to commercialize and sell products that generate royalties; if those partners underperform or make unfavorable decisions, SWK's income is directly affected.
• Merger execution risk — The planned merger with Runway Growth Finance Corp. may not close on expected terms or timing, and the announcement could disrupt operations or client relationships.

Outlook

Management expects the merger with Runway Growth Finance Corp. to close in late Q4 2025 or Q1 2026, which would result in SWK becoming a wholly owned subsidiary and ultimately absorbed into Runway. The company will continue to focus on its finance receivables portfolio, leveraging its effective yield of 16.9% and a tangible financing book value of $19.42 per share (up 12.4% year-over-year after adjusting for the special dividend). No forward guidance was provided beyond the merger.